Teladoc (TDOC) Coverage Initiated by Analysts at Citigroup

Investment analysts at Citigroup initiated coverage on shares of Teladoc (NYSE:TDOC) in a report released on Thursday, The Fly reports. The brokerage set a “buy” rating on the health services provider’s stock.

A number of other equities analysts have also recently weighed in on TDOC. Cowen reaffirmed an “outperform” rating and set a $39.00 price target on shares of Teladoc in a research note on Saturday, September 30th. Piper Jaffray Companies reissued a “buy” rating and issued a $42.00 price objective on shares of Teladoc in a research note on Friday, September 29th. Cantor Fitzgerald reissued a “hold” rating and issued a $31.00 price objective on shares of Teladoc in a research note on Tuesday, September 26th. ValuEngine upgraded shares of Teladoc from a “sell” rating to a “hold” rating in a report on Sunday. Finally, Zacks Investment Research upgraded shares of Teladoc from a “sell” rating to a “hold” rating in a report on Thursday, September 21st. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and eleven have given a buy rating to the company. Teladoc has an average rating of “Buy” and a consensus target price of $39.15.

Teladoc (NYSE TDOC) opened at $36.85 on Thursday. The company has a debt-to-equity ratio of 0.83, a quick ratio of 5.08 and a current ratio of 5.08. Teladoc has a 12 month low of $15.65 and a 12 month high of $37.90. The firm has a market cap of $2,065.19, a price-to-earnings ratio of -25.59 and a beta of 0.42.

Teladoc (NYSE:TDOC) last posted its quarterly earnings results on Wednesday, November 1st. The health services provider reported ($0.55) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.25). Teladoc had a negative return on equity of 21.59% and a negative net margin of 39.61%. The company had revenue of $68.70 million for the quarter, compared to analyst estimates of $67.53 million. During the same period last year, the company earned ($0.33) earnings per share. The business’s revenue for the quarter was up 112.0% compared to the same quarter last year. research analysts predict that Teladoc will post -1.56 earnings per share for the current year.

In related news, CEO Jason N. Gorevic sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $32.10, for a total value of $642,000.00. Following the transaction, the chief executive officer now owns 838,261 shares in the company, valued at $26,908,178.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Jason N. Gorevic sold 100,000 shares of the firm’s stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $32.99, for a total transaction of $3,299,000.00. Following the completion of the transaction, the chief executive officer now owns 718,261 shares in the company, valued at approximately $23,695,430.39. The disclosure for this sale can be found here. Insiders sold 210,000 shares of company stock worth $6,889,350 in the last 90 days. 4.47% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of TDOC. Iguana Healthcare Management LLC acquired a new stake in Teladoc in the third quarter valued at approximately $1,160,000. Neuberger Berman Group LLC grew its position in Teladoc by 53.4% in the third quarter. Neuberger Berman Group LLC now owns 25,785 shares of the health services provider’s stock valued at $855,000 after acquiring an additional 8,971 shares in the last quarter. California Public Employees Retirement System grew its position in Teladoc by 52.1% in the third quarter. California Public Employees Retirement System now owns 11,409 shares of the health services provider’s stock valued at $378,000 after acquiring an additional 3,909 shares in the last quarter. Bamco Inc. NY grew its position in Teladoc by 751.9% in the third quarter. Bamco Inc. NY now owns 1,455,900 shares of the health services provider’s stock valued at $48,263,000 after acquiring an additional 1,285,000 shares in the last quarter. Finally, Granahan Investment Management Inc. MA acquired a new stake in Teladoc in the third quarter valued at approximately $14,569,000.

WARNING: This article was posted by American Banking and Market News and is the sole property of of American Banking and Market News. If you are accessing this article on another site, it was illegally copied and reposted in violation of US and international copyright legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2018/01/04/teladoc-tdoc-coverage-initiated-by-analysts-at-citigroup.html.

Teladoc Company Profile

Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.